drugset
drugset / Trial / NCT02782182

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

NCT02782182 ↗

Phase 1 Terminated 1 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.

Timeline

Start
2016-06-28
Primary completion
2018-03-29
Completion
2018-03-29

Outcome

Outcome not reported

Stopped (Enrollment): “Closed early due to poor accrual.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — —
Subject Leucovorin Small molecule — —
Subject Oxaliplatin Small molecule — —

Indications

pancreatic ductal adenocarcinoma